Imagine being able to predict your risk of developing diabetes with a simple blood test – a heads-up that could potentially change your life. That's the exciting possibility emerging from new research focusing on prediabetes. But here's the thing: prediabetes isn't a one-size-fits-all condition. It's a complex, multifaceted metabolic disorder, and some people are at far greater risk than others. Scientists are now using the power of artificial intelligence (AI) to unravel this complexity and pinpoint those most vulnerable to developing type 2 diabetes and its complications. This breakthrough could lead to earlier, more targeted interventions, potentially preventing or delaying the onset of this widespread disease. This research comes from several partner institutes of the German Center for Diabetes Research (DZD).*
Prediabetes is a critical window of opportunity. It's a stage where lifestyle changes can make a real difference, potentially halting the progression to type 2 diabetes or even reversing the condition. Early interventions, such as diet and exercise modifications, can be incredibly effective. However, the key lies in accurately assessing individual risk. Some individuals with prediabetes face only a slight chance of developing the disease, while others are highly likely to progress to diabetes and suffer complications, requiring more aggressive interventions. The challenge? Figuring out who falls into which category.
Previous research (https://pubmed.ncbi.nlm.nih.gov/33398163/) ** by the DZD and collaborators revealed that prediabetes can be categorized into at least six distinct clusters. These clusters differ significantly in their metabolic profiles, how the disease progresses, and the risk of developing complications. Three clusters represent a moderate risk, while the other three indicate a high risk of type 2 diabetes and related complications. Identifying which cluster a person belongs to currently involves extensive clinical evaluations, including oral glucose tolerance tests, detailed insulin measurements, and advanced imaging techniques. These tests, while valuable, are time-consuming and expensive.
"This detailed classification is of great value, but is simply too time-consuming for routine practice," explains Dr. Meriem Ouni, a researcher at the German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), a DZD partner, and the study's corresponding author. "For this reason, we wanted to examine whether risk groups could also be identified using easily accessible biomarkers in the blood." In essence, the researchers aimed to find a simpler, more practical way to assess prediabetes risk.
The researchers focused on epigenetic markers – modifications to DNA that can influence gene expression without altering the underlying DNA sequence. Think of it like adding annotations to a recipe; the recipe (DNA) stays the same, but the annotations (epigenetic markers) can change how the recipe is interpreted and executed. They analyzed blood samples from participants in multiple study cohorts, all with known prediabetes risk profiles. The goal was to identify a pattern of epigenetic markers that could accurately predict a person's risk of developing type 2 diabetes.
Their findings were remarkable: By analyzing 1,557 epigenetic markers in the blood, they could correctly assign individuals to the high-risk clusters with approximately 90% accuracy – and this held true even in an independent validation cohort. This is a significant achievement, suggesting that these markers provide a reliable "biological fingerprint" of prediabetes risk. And this is the part most people miss: Many of these markers are specific to particular clusters, indicating that they reflect different underlying biological pathways involved in the development of diabetes and its complications. This level of detail could be crucial for tailoring interventions to specific individuals.
Interestingly, many of the identified markers had already been linked to type 2 diabetes, chronic inflammation, and cardiovascular and kidney diseases in previous studies. This further supports the idea that these markers play a key role in the development and progression of prediabetes. They could also explain the heterogeneity of prediabetes – why some people progress to diabetes while others don't.
"Our results suggest that epigenetic markers in the blood are an effective early warning system," says Prof. Annette Schürmann, Director of the DZD and the study's last author. These markers not only reflect the current metabolic state but also provide clues about the future course of the disease. "They make it possible to identify people with a particularly high risk of diabetes and complications early on—even before severe metabolic deterioration occurs." This could be a game-changer for prevention efforts.
What does this mean for the future? In the long term, this approach could revolutionize how we prevent and manage prediabetes. Instead of relying on time-consuming and expensive clinical examinations, a simple, standardized blood test could provide a differentiated risk assessment, allowing for more targeted and personalized preventive measures. This could enable earlier intervention and more effective prevention strategies.
"Our next step is therefore to convert our insights into a practical test," explains Ouni. The immediate goal is to narrow down the number of markers to a more manageable set. Following this, the plan is to develop a custom-designed analysis chip that can easily and cost-effectively identify prediabetes risk clusters in routine diagnostics. But here's where it gets controversial... Could this lead to insurance companies using this information to deny coverage, or employers discriminating against individuals deemed at high risk? This is a crucial ethical consideration that needs to be addressed.
Original publication:
Singh, A., Schwartzenberg, R.Jv., Wagner, R. et al. Stratifying high-risk prediabetes clusters using blood-based epigenetic markers. Biomark Res (2026). https://doi.org/10.1186/s40364-025-00887-8
*Several partner institutes of the German Center for Diabetes Research (DZD) e.V. participated in the study:
• German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE)
• Institute for Diabetes Research and Metabolic Diseases (IDM) of Helmholtz Munich at the Eberhard-Karls-University of Tübingen
• German Diabetes Center in Düsseldorf (DDZ)
• Paul Langerhans Institute Dresden of Helmholtz Munich at the University Hospital and Faculty of Medicine Carl Gustav Carus of TU Dresden (PLID)
** https://pubmed.ncbi.nlm.nih.gov/33398163/
What do you think about the potential of epigenetic markers to predict disease risk? Are you excited about the possibilities, or concerned about the ethical implications? Share your thoughts in the comments below! What other diseases could this approach be applied to?
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here (https://www.miragenews.com/blood-epigenetic-markers-enhance-prediabetes-1607071/) .
